Early basal insulin in patients with type 2 diabetes achieves glycemic control better than sitagliptin, but with greater risk of hypoglycemia

mdCurrent Conference Report: 72nd Annual Scientific Sessions of the American Diabetes Association

Adding basal insulin (insulin glargine) as a second-line treatment after metformin is superior to adding sitagliptin in achieving glycemic control in patients with type 2 diabetes, according to study data presented at the 72nd Annual (2012) Scientific Sessions of the American Diabetes Association (ADA).

Key Point: The early addition of basal insulin to the regimen of patients with uncontrolled type 2 diabetes was superior to adding sitagliptin to achieve glycemic control in a recent study. This strategy could be useful for patients with uncontrolled type 2 diabetes.

“The results of this study support the option of introducing basal insulin (glargine) in patients with type 2 diabetes inadequately controlled by metformin, with the potential for long-term benefits arising from the achievement of optimum glycemic control early in the course of the disease,” said the study’s co-investigator Pablo J. Aschner, MD, MSc, professor of medicine, endocrinology unit, Javeriana University, Bogotá, Columbia.

The International Diabetes Federation estimated that 61.3 million people in India had diabetes in 2011, and that number is expected to rise to 101.2 million...

Log in or register for free to continue reading
Register Now For Free Already Registered? Log In
This entry was posted in Diabetes, Primary Care and tagged , , , , , , , , , , . Volume: .

One Comment

  1. krishnananda olety veerappasetty
    Posted Aug 2013 at 4:39 pm | Permalink

    good articles

Post a Comment

You must be logged in to post a comment.